Brief: Inmune Bio Completes Blinded Interim Analysis Of Phase II Alzheimer's Disease Trial

Inmune Bio

27/06/2024 13:38

June 27 (Reuters) - INmune Bio Inc  INMB.O :
    * INMUNE BIO, INC. COMPLETES BLINDED INTERIM ANALYSIS OF
PHASE II
ALZHEIMER’S DISEASE TRIAL
    * INMUNE BIO INC: PLANNED INTERIM ANALYSIS CONFIRMS ACCURACY
OF
SAMPLE SIZE CALCULATIONS AND STATISTICAL POWER FOR EMACC,
PRIMARY ENDPOINT
    * INMUNE BIO INC: INTERIM ANALYSIS, PERFORMED BY A
THIRD-PARTY,
DEMONSTRATED NO NEED TO CHANGE TRIAL DESIGN OR SIZE

Source text for Eikon:  ID:nGNX4dTgmK 
Further company coverage:  INMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))